Nadesalingam, Angalee, Cantoni, Diego, Aguinam, Ernest T, Chan, Andrew CY, Paloniemi, Minna, Ohlendorf, Luis, George, Charlotte, Carnell, George, Lyall, Jon, Ferrari, Matteo, and others. (2023) Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies. The Lancet Microbe, 4 (2). e58-e59. ISSN 2666-5247. (doi:10.1016/S2666-5247(22)00297-X) (KAR id:97749)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/121kB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1016/S2666-5247%2822%2900297-X |
Abstract
Despite the success of COVID-19 vaccination programmes in reducing morbidity and mortality, a substantial number of individuals in the general population respond poorly to SARS-CoV-2 vaccination. Furthermore, only about 20% of individuals throughout low-income countries have received their first dose of the SARS-CoV-2 vaccine. Neutralising antibodies are a key correlate to protection from COVID-19, with booster vaccines offered to increase protection from new variants. However, poor responsiveness to immunisation increases the risk of infection and disease. The CDC reported that patients with compromised immune systems accounted for about 12% of adult COVID-19 hospital admissions and had higher rates of intensive care admissions and in-hospital deaths compared with non-immunocompromised inpatients, in both vaccinated and unvaccinated populations. Although a heterogeneous group, the majority of patients with immunodeficiency show variable and weaker antibody-mediated responses post-vaccination to SARS-CoV-2 than individuals without immunodeficiency. In March, 2022, a UK report revealed 45·5% of immunocompromised individuals received a booster vaccination dose. However, without immune monitoring it remains unclear which individuals within this high-risk population have sufficient immunity.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1016/S2666-5247(22)00297-X |
Uncontrolled keywords: | Covid-19; SARS-CoV-2 vaccination, immunodeficiency |
Subjects: | Q Science > QR Microbiology > QR355 Virology |
Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
Funders: | UK Research and Innovation (https://ror.org/001aqnf71) |
Depositing User: | Nigel Temperton |
Date Deposited: | 02 Nov 2022 08:36 UTC |
Last Modified: | 04 Mar 2024 19:02 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/97749 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):